Innovators from across the globe gathered in Las Vegas, Nevada, once again for the annual Consumer Electronics Show. The heralded conference known for showcasing the latest and most transformative technologies has begun inviting more leading healthcare companies to the influential event as the medical sector becomes increasingly digitally oriented. In an interview at CES 2024, Xenco Medical Founder and CEO Jason Haider detailed a groundbreaking technology that intersects the worlds of biomaterials and digital health. The acclaimed medical technology company unveiled its TrabeculeX Continuum at the world-renowned tech conference last week. Consisting of the company's TrabeculeX Bioactive Matrix and its TrabeculeX Recovery App, the TrabeculeX Continuum is the first technology-enabled bridge between regenerative medical technologies and digital health.
The fascinating offering unifies a patient's biomaterial implantation and postoperative journey. CEO Jason Haider outlined the driving vision that spurred the creation of this bridging technology by noting that the disruptive medical technology company wanted to "bridge the gap between science and empathy" and to "challenge itself to address not just an instance of care but the entire spectrum of a patient's journey." Enabling surgeons who have implanted Xenco Medical's TrabeculeX Bioactive Matrix to enroll patients in the TrabeculeX Recovery App and engage in both Remote Therapeutic Monitoring and asynchronous video and text messaging, the TrabeculeX Continuum unifies a patient's biomaterial implantation and postoperative journey.
Describing the interaction between the beta-tricalcium phosphate and bioglass embedded in each TrabeculeX Bioactive Matrix, Haider noted that the interplay between the compounds created a "microscopic symphony." When asked about the impetus behind the novel offering, he highlighted that the company wanted patients to be treated as "partners rather than pathologies." The San Diego-headquartered company, which was named one of the World's Most Innovative Companies by Fast Company Magazine, has gained a strong reputation for developing breakthrough technologies in recent years. The HIPPA-compliant TrabeculeX Recovery App allows surgeons who've used the Xenco Medical biomaterial in their patient to prescribe patient-specific physical rehabilitation plans and remotely monitor progress while engaging in asynchronous video and text messaging.
When discussing the regenerative biomaterial component of the TrabeculeX Continuum, Haider underscored the unique surface topography featured in the TrabeculeX Bioactive Matrix and that the company wanted to "start at the sub-micron scale" when engineering its new resorbable implant. When asked about the company's future plans, Haider encapsulated the path forward by noting that Xenco Medical's approach to care would continue to include an emphasis on both "breadth and depth" in its technologies and that a commitment to the "longitudinal recovery of each patient" would be imbued into each of its surgical devices. As always, the Consumer Electronics Show offered a fascinating array of captivating technologies. With advancements in digital health accelerating each year, next year's convening promises to be just as breathtaking.
